Key result
Selective ERα activation boosts right ventricular capillary density up to ~45% in pulmonary hypertension models.
Why the study?
The mechanisms and regulators of adaptive angiogenesis and right ventricular endothelial cell function in pulmonary hypertension are incompletely understood, and whether 17β-estradiol modifies these processes in right ventricular failure remained unknown.
Does 17β-estradiol and estrogen receptor α activation promote right ventricular angiogenesis and endothelial cell homeostasis via apelin signaling in models of pulmonary hypertension and right ventricular failure?
Does 17β-estradiol and estrogen receptor α activation promote right ventricular angiogenesis and endothelial cell homeostasis via apelin signaling in models of pulmonary hypertension and right ventricular failure?
This preclinical study demonstrates that 17β-estradiol promotes right ventricular angiogenesis and preserves capillary density in pulmonary hypertension via an estrogen receptor α and apelin receptor-dependent signaling axis, identifying selective ERα activation as a potential therapeutic strategy for right ventricular failure.
Answers are grounded in this paper and cite their sources.
May support ERα-apelin targeting for RV angiogenesis in PH; extends preclinical estrogen data but leaves open clinical translation.
Right ventricular (RV) failure is the major cause of mortality in pulmonary hypertension (PH). Adaptive angiogenesis and RV endothelial cell (RVEC) function are major modifiers of RV adaptation in PH, but the underlying mechanisms and their regulators remain incompletely understood. RV adaptation in PH is sexually dimorphic, and 17β-estradiol (E2) exerts protective effects on RV cardiomyocytes. Whether E2 modifies angiogenesis and RVEC function in RV failure remains unknown. We hypothesized that E2 and estrogen receptor α (ERα) promote RV angiogenesis and RVEC homeostasis in PH and aimed to identify underlying mechanisms. We assessed E2's angiogenic effects using cultured human cardiac microvascular endothelial cells (hCMVECs), RVECs from PH patients with RV failure, and RVECs from sugen/hypoxia (SuHx) and monocrotaline rat models. In vivo, we evaluated RV capillary density in PH rats treated with E2 or ERα-selective agonist. Apelin signaling was evaluated via apelin receptor (APLNR) blockade and knockdown studies. E2 preserved angiogenesis in male hCMVECs and RV capillary density in male and female SuHx-PH rats. E2 reversed angiogenic alterations in RVECs from SuHx-PH rats via APLNR signaling. In RVECs from RV failure patients, E2 stimulated vascular network formation. In rat and human PH-RVECs, ERα was necessary and sufficient to mediate E2-induced angiogenesis. Activation of ERα with ERα-specific agonist restored RV capillary density in vivo. ERα-mediated angiogenesis required apelin signaling. These data indicate that E2 promotes RV angiogenesis via ERα and apelin signaling and identify a novel ERα-apelin axis in RVECs as a potential therapeutic target to restore RV vascular integrity in PH.
No takes yet. Share an insight, caveat, or question.
Bousseau et al. (2026) studied Pulmonary hypertension with right ventricular failure. 17β-estradiol (E2) or estrogen receptor α (ERα)-selective agonists (PPT, BTPα) vs. Untreated or vehicle-treated pulmonary hypertension controls, ERβ agonist (DPN), or apelin receptor antagonist (ML221) was evaluated on Right ventricular capillary density (in vivo) and vascular network formation, migration, and proliferation (in vitro). 17β-estradiol and selective ERα activation increased RV capillary density by 25-45% in pulmonary hypertension rats and enhanced human RVEC vascular network formation by ~20% via apelin.
Synapse has enriched 10 related papers. Consider them for comparative context: